Analysts expect Caris Life Sciences, Inc. to report revenue of 271.61 M for Q3 26, against a range of 251.16 M to 292.05 M. The most recent reported quarter, Q2 26, came in at 263.71 M, a 4.7% beat against the 251.80 M consensus.
| Metric | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 105.71 M | 115.45 M | 115.57 M | 111.11 M | 105.58 M | 107.57 M | 103.42 M | 105.02 M | 75.73 M | 79.05 M | 81.57 M | 80.80 M | 120.91 M | 181.40 M | 216.83 M | 292.89 M | 216.17 M | 263.71 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 110.08 M | 127.99 M | 121.85 M | 127.57 M | 132.44 M | 117.83 M | 112.29 M | 99.48 M | 117.59 M | 78.45 M | 87.18 M | 86.04 M | - | 153.25 M | 195.46 M | 258.51 M | 218.80 M | 275.04 M | 292.05 M | 287.19 M | 297.66 M | 310.37 M | 302.16 M | 376.50 M | 341.94 M | 403.76 M | ||||||||||
| Low Estimate | 99.84 M | 104.90 M | 103.15 M | 112.43 M | 111.20 M | 97.52 M | 95.72 M | 92.97 M | 99.93 M | 70.60 M | 81.17 M | 73.68 M | - | 131.41 M | 175.49 M | 237.35 M | 182.94 M | 228.57 M | 251.16 M | 264.81 M | 257.98 M | 264.18 M | 281.12 M | 313.25 M | 305.28 M | 349.87 M | ||||||||||
| Consensus Estimate | 104.96 M | 116.45 M | 112.50 M | 120.00 M | 121.82 M | 107.67 M | 104.00 M | 96.22 M | 108.76 M | 74.53 M | 84.18 M | 79.86 M | - | 142.33 M | 185.48 M | 247.93 M | 200.87 M | 251.80 M | 271.61 M | 276.00 M | 277.82 M | 287.27 M | 291.64 M | 344.87 M | 323.61 M | 376.82 M |
Analysts expect Caris Life Sciences, Inc. to report earnings per share of 0.03 for Q3 26, against a range of 0.03 to 0.03. The most recent reported quarter, Q2 26, came in at 0.00, a 100.0% miss against the 0.01 consensus.
| Metric | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.90 | 1.03 | 0.89 | 0.87 | 0.69 | 0.74 | 0.54 | 0.67 | 0.78 | 1.04 | 1.76 | 1.85 | -0.35 | -7.97 | 0.08 | 0.28 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 0.92 | 1.00 | 1.09 | 1.03 | 0.99 | 0.77 | 0.69 | 0.59 | 0.52 | 0.90 | 1.26 | 1.65 | - | -0.20 | -0.16 | 0.05 | -0.02 | 0.01 | 0.03 | 0.11 | 0.04 | 0.09 | 1.16 | 0.72 | -0.25 | -0.87 | ||||||||||
| Low Estimate | 0.78 | 0.82 | 0.95 | 0.87 | 0.81 | 0.63 | 0.63 | 0.53 | 0.44 | 0.80 | 1.14 | 1.51 | - | -0.22 | -0.18 | 0.05 | -0.02 | 0.01 | 0.03 | 0.09 | 0.04 | 0.07 | 1.08 | 0.66 | -0.27 | -1.05 | ||||||||||
| Consensus Estimate | 0.85 | 0.91 | 1.02 | 0.95 | 0.90 | 0.70 | 0.66 | 0.56 | 0.48 | 0.85 | 1.20 | 1.58 | - | -0.21 | -0.17 | 0.05 | -0.02 | 0.01 | 0.03 | 0.10 | 0.04 | 0.08 | 1.12 | 0.69 | -0.26 | -0.96 |
Pull Wall Street consensus for Caris Life Sciences, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=CAI&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "CAI", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=CAI&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();